ABL1 and graft versus host disease: A GBM method, using the highest BCR/ABL1 levels, as measured in different time points, presence of GvHD, time of prediction (days after HSCT), BCR/ABL1 levels at the time of prediction, and administration or not of tyrosine kinase inhibitors, was developed with a sensitivity of 0.91 to predict relapse in this population.